OBJECTIVE: To probe into the effects of lanthanum carbonate combined with low calcium dialysis on calcium and phosphorus metabolism and intact parathyroid hormone（ i PTH） in elderly patients with maintenance hemodialysis. METHODS: Totally 60 elderly patients with maintenance hemodialysis admitted into Hemodialysis Center

Beijing Tongren Hospital

Capital Medical University from Jan. 2019 to Mar. 2020 were extracted to be divided into two groups via the random number table. The observation group（ n = 30） was treated with low calcium dialysis combined with lanthanum carbonate

while the control group（ n = 30） received low calcium dialysis combined with calcium carbonate. The serum calcium

serum phosphorus

calcium phosphorus product

i PTH and adverse drug reactions of two groups were observed and recorded before treatment

after treatment of 1 month

2 months and 3 months. And statistical analysis was performed. RESULTS: The serum calcium

serum phosphorus and calcium phosphorus product of the observation group after treatment were significantly lower than those before treatment

and the difference was statistically significant（ P < 0. 05）. Compared with before treatment

there was no statistically significant difference in serum calcium

serum phosphorus and calcium-phosphorus product in the control group after treatment（ P > 0. 05）. The difference of the above indicators after treatment between two groups was statistically significant（ P< 0. 05）. After treatment

the levels of i PTH in two groups were significantly lower than those before treatment

yet the reduction in the observation group was more significant

and the difference was statistically significant（ P< 0. 05）. The total incidence of adverse drug reactions in the observation group was 33. 33%（ 10/30）

significantly higher than that in the control group（ 6. 67%

2/30）

the difference was statistically significant（ P <0. 05）. CONCLUSIONS: Lanthanum carbonate combined with low calcium dialysis can effectively reduce the serum calcium

serum phosphorus

calcium phosphorus product and i PTH in elderly patients with maintenance hemodialysis

which can help to correct the hypercalcemia and hyperphosphatemia

prevent the hyperparathyroidism and regulate the abnormal bone material metabolism to avoid hypotransformation bone disease

yet the incidence of adverse drug reactions is slightly higher

and attention should be paid to the prevention and control of adverse drug reactions in clinical application.